AI and Healthcare

Cracking AI in Healthcare: Real Use Cases & Missed Opportunities - Full Podcast

AI is reshaping healthcare, from clinical workflows to drug discovery and the rise of full-stack biotech companies. But what are the real challenges, and where is AI falling short? Mika Newton sits down with Krish Ramadurai from AIX Ventures to break down the complexities of AI in healthcare, the importance of domain expertise, and the push to automate clinical development. They also discuss how startups can navigate the industry’s regulatory landscape and what investors are looking for in AI-driven healthcare solutions. Whether you're in biotech, investing, or just curious about the future of AI, this discussion offers valuable insights.

Can AI Cure Cancer Before It Starts? Dr. Azra Raza Explains - Full Podcast

Join Dr. Sanjay Juneja and Columbia University professor Dr. Azra Raza in an in-depth discussion about the transformative potential of AI and technology in early cancer detection. Dr. Raza shares her insights on how continuous monitoring and innovative technologies could find cancer at the 'first cell stage,' long before traditional methods. Learn about her journey from pediatric oncology to establishing one of the richest tissue repositories, and discover how AI-powered implantable devices could revolutionize the future of healthcare. This episode sheds light on the untapped possibilities in proactive cancer care and the critical shift needed to focus on early detection.

Are Current AI Developments Sustainable?

This episode features Nigam Shah discussing the sustainability of AI in healthcare, focusing on challenges in development, validation, and regulation. The conversation explores the limitations of current AI models, the evolving role of governance, and the need for localized validation to ensure accuracy and relevance.

Rethinking AI in Healthcare: Insights from Dr. Nigam Shah - Full Podcast

In this episode, Mika Newton speaks with Dr. Nigam Shah, a professor at Stanford and Chief Data Scientist at Stanford Healthcare, about the challenges and opportunities of AI in healthcare. They discuss the sustainability of AI development, the complexities of regulation, and the importance of localized validation. The conversation explores how AI can enhance clinical decision-making, optimize healthcare resources, and expand patient access while addressing barriers in implementation, governance, and data sharing.

Breaking Healthcare’s Bottleneck: AI, Data & Policy Fixes with Bob Battista - Full Podcast

This podcast episode explores the intersection of AI and healthcare, focusing on drug development, repurposing, and access to medical treatments. Mika Newton speaks with Bob Battista about the challenges of sharing pharmaceutical data, regulatory barriers, and how AI could enhance clinical decision-making. They discuss real-world data, patient knowledge, and the role of technology in optimizing treatment pathways. The conversation also touches on privacy laws, governance, and the potential for AI to empower patients with better access to medical insights. Viewers will gain a deeper understanding of how innovation and policy changes could improve healthcare outcomes.

Who is responsible for AI decisions?

Mika Newton and Bob Battista explore how AI could reshape healthcare by giving patients greater control over their medical decisions. They discuss the potential for AI to process vast amounts of clinical data, improve access to relevant treatments, and bridge gaps in health literacy. The conversation also raises important questions about data sharing, patient autonomy, and the future of AI-driven support in medicine.

How is AI Changing Healthcare Decision Making?

Mika Newton and Bob Battista discuss how AI is shaping healthcare decision-making. They explore its role in analyzing clinical evidence, updating guidelines dynamically, and personalizing treatment recommendations. The conversation also highlights challenges like regulatory restrictions and data silos that limit AI’s full potential in the industry.

What is the biggest hurdle in drug repurposing today?

Drug repurposing offers a way to find new treatments using existing medications, but regulatory hurdles and financial disincentives often prevent progress. Mika Newton and Bob Battista examine the challenges of data sharing in the pharmaceutical industry, the high costs of clinical trials, and why companies hesitate to pursue niche indications. They also explore potential policy solutions that could encourage collaboration and make more life-saving treatments accessible to patients.